Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Limkakeng, Alexander T., Laura-Leigh Rowlette, Ace Hatch, Andrew B. Nixon, Olga Ilkayeva, David Corcoran, Jennifer Modliszewski, Shannon Michelle Griffin, Geoffrey S. Ginsburg, and Deepak Voora. “A precision medicine approach to stress testing using metabolomics and microribonucleic acids.” Per Med, April 25, 2022. https://doi.org/10.2217/pme-2021-0021.

PMID
35466688
Full Text

Quintanilha, Julia C. F., Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B. Nixon, and Federico Innocenti. “Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.” Br J Clin Pharmacol, April 18, 2022. https://doi.org/10.1111/bcp.15356.

PMID
35437784
Full Text

Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, B. Silva, N. Gulbahce, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Bronchoalveolar Lavage Fluid (BALF) as a Compartment for DonorDerived Cell-Free DNA (dd-cfDNA) Assessment in Lung Recipients.” In Journal of Heart and Lung Transplantation, 41:S155–S155, 2022.

Scholars@Duke

Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) for Discriminating Acute Lung Allograft Injury in a Multicenter Cohort.” In Journal of Heart and Lung Transplantation, 41:S74–S74, 2022.

Scholars@Duke

Lipsyc-Sharf, Marla, Sui Zhang, Fang-Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I-Wen Chang, et al. “Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.” J Natl Cancer Inst 114, no. 3 (March 8, 2022): 427–35. https://doi.org/10.1093/jnci/djab200.

PMID
34636852
Full Text

Jia, Jingquan, Lauren Howard, Yingmiao Liu, Mark D. Starr, John C. Brady, Donna Niedzwiecki, John H. Strickler, and Andrew B. Nixon. “Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.” Cancer Chemother Pharmacol 89, no. 3 (March 2022): 413–22. https://doi.org/10.1007/s00280-022-04404-8.

PMID
35171350
Full Text

Shah, Ankoor, Jan Storek, Rob Woolson, Ashley Pinckney, Lynnette Keyes-Elstein, Paul K. Wallace, Gregory D. Sempowski, et al. “Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.” Rheumatology (Oxford), February 2, 2022. https://doi.org/10.1093/rheumatology/keac015.

PMID
35108379
Full Text

Mettu, Niharika B., Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, et al. “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.” Jama Netw Open 5, no. 2 (February 1, 2022): e2149040. https://doi.org/10.1001/jamanetworkopen.2021.49040.

PMID
35179586
Full Text

Park, Haeseong, Aravind Sanjeevaiah, Peter Joel Hosein, Rutika Mehta, Ramon Jin, Patrick Grierson, Rama Suresh, et al. “Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.” In Journal of Clinical Oncology, 40:284–284. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.4_suppl.284.

Full Text

Quintanilha, Julia C. F., Yingmiao Liu, Amy S. Etheridge, Akram Yazdani, Hedy L. Kindler, William Kevin Kelly, Andrew B. Nixon, and Federico Innocenti. “Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).” Angiogenesis 25, no. 1 (February 2022): 47–55. https://doi.org/10.1007/s10456-021-09799-1.

PMID
34028627
Full Text

Pages